Psoriasis

Below is a list of our psoriasis studies that are currently enrolling.

A Phase 3 Open-label Pediatric Safety Study of a Study Drug in Pediatric Subjects in Children with Mild to Moderate Plaque Psoriasis

Population: Children aged six to seventeen years old
Study Condition: Mild to moderate plaque psoriasis
Study Design: The purpose of this study is to assess the safety and tolerability of a study drug in pediatric subjects ages 6 through 17 years with mild to moderate plaque psoriasis. This study will include 12 visits with a total study duration of up to 285 days.
Compensation may be provided upon study participation

Please contact Courtney Rowley for more information regarding ongoing psoriasis studies.